Literature DB >> 923097

Human serum amine oxidase. Enzyme activity in severely burnt patients and in patients with cancer.

R Lewinsohn.   

Abstract

During a study of serum amine oxidase (SAO) levels in patients with fibrotic disease processes, 127 patients (100 adults and 27 children) with moderate to severe burns were investigated. Of these, 55 adults and 20 children, classified as severe, had enzyme levels of 2.7 +/- 0.3 and 4.6 +/- 0.9 McEwen Units (McE.U) (mean +/- S.E.) respectively, which, compared with those for normal healthy adults (18.3 +/- 0.6 McE.U), gave a difference of striking significance (t=21.05 for 130 d.f., and t=10.33 for 95 d.f., respectively). Subsequently, 125 patients with proven cancer were studied. 52 percent of the untreated and 41 percent of the treated showed remarkably low enzyme activity. The mean of the group of untreated patients was 9.6 +/- 1.1 McE.U, that of the treated 11.6 +/- 1.0 McE.U, and that of the entire group 10.7 +/- 0.7 McE.U. The difference between these values and normal activity is highly significant (p less than 10(-6)). Sequential SAO estimations on severly burnt patients and those with cancer established the time course of enzyme activity in these patients. Our observations suggest that estimation of SAO activity may be useful not only for the classification, monitoring and prognosis of severe burns, but also in the diagnosis of cancer and the evaluation of its treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 923097     DOI: 10.1016/0009-8981(77)90055-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.

Authors:  Håkan Garpenstrand; Michael Bergqvist; Daniel Brattström; Anders Larsson; Lars Oreland; Patrik Hesselius; Gunnar Wagenius
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

2.  Inhibition of monoamine oxidase and semicarbazide-sensitive amine oxidase by mexiletine and related compounds.

Authors:  M Eriksson; C J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

3.  New factors relevant to polyamine levels in cancer patients.

Authors:  W A Boggust; M Moriarty; S O'Connell
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568

4.  Biochemical aspects and functional role of the copper-containing amine oxidases.

Authors:  F Buffoni; G Ignesti
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 5.  Hepatic consequences of vascular adhesion protein-1 expression.

Authors:  Chris J Weston; David H Adams
Journal:  J Neural Transm (Vienna)       Date:  2011-04-22       Impact factor: 3.575

Review 6.  SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.

Authors:  Mercedes Unzeta; Mar Hernàndez-Guillamon; Ping Sun; Montse Solé
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.